174 related articles for article (PubMed ID: 2180855)
21. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
23. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.
Nashan D; Müller ML; Grabbe S; Wustlich S; Enk A
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1305-18. PubMed ID: 17958834
[TBL] [Abstract][Full Text] [Related]
24. [The present status of the multidisciplinary treatment of malignant melanoma].
Ishihara K; Hayasaka K; Ikegawa S; Kageshita T
Gan No Rinsho; 1985 Jul; 31(9 Suppl):1073-8. PubMed ID: 4057571
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
27. Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
Lui P; Cashin R; Machado M; Hemels M; Corey-Lisle PK; Einarson TR
Cancer Treat Rev; 2007 Dec; 33(8):665-80. PubMed ID: 17919823
[TBL] [Abstract][Full Text] [Related]
28. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Carbone PP; Costello W
Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
[TBL] [Abstract][Full Text] [Related]
29. [Combination chemotherapy of disseminated skin melanoma with nitrosomethylurea].
Perevodchikova NJ; Moros LW; Kogonia LM
Arch Geschwulstforsch; 1986; 56(4):273-81. PubMed ID: 3530176
[TBL] [Abstract][Full Text] [Related]
30. Curative and palliative aspects of regional chemotherapy in combination with surgery.
Müller H; Hilger R
Support Care Cancer; 2003 Jan; 11(1):1-10. PubMed ID: 12527948
[TBL] [Abstract][Full Text] [Related]
31. [Adjuvant chemotherapy of malignant melanoma with DTIC. Lack of effect in stage I. Possible improvement of the prognosis for survival in stage IIb].
Garbe C; Guenther-Eymann K; Stadler R; Orfanos CE
Hautarzt; 1988 Apr; 39(4):205-12. PubMed ID: 3384660
[TBL] [Abstract][Full Text] [Related]
32. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
Flaherty LE
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
[TBL] [Abstract][Full Text] [Related]
33. Clinical trials in disseminated malignant melanoma.
Kleeberg UR
Anticancer Res; 1987; 7(3 Pt B):423-7. PubMed ID: 3307600
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
[TBL] [Abstract][Full Text] [Related]
35. The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma.
Young DW; Lever RS; English JS; MacKie RM
Cancer; 1985 May; 55(9):1879-81. PubMed ID: 2579722
[TBL] [Abstract][Full Text] [Related]
36. [Chemotherapy of skin and soft tissue tumors].
Herrmann R
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():919-21. PubMed ID: 1983679
[TBL] [Abstract][Full Text] [Related]
37. [Dacarbacine (DTIC) in the therapy of a malignant disease. A review (author's transl)].
Huber H; Grünewald K
Wien Klin Wochenschr; 1978 Dec; 90(24):861-4. PubMed ID: 369151
[TBL] [Abstract][Full Text] [Related]
38. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
39. [Immunology and therapy of malignant melanoma (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1977 Sep; 89(18):612-22. PubMed ID: 906525
[TBL] [Abstract][Full Text] [Related]
40. [DTIC in the therapy of solid tumours (author's transl)].
Kokron O; Pridun N; Zischinsky W
Wien Klin Wochenschr; 1978 Dec; 90(24):864-7. PubMed ID: 741753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
